Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2017 March;56(1) > Minerva Pneumologica 2017 March;56(1):33-46

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

 

REVIEW   

Minerva Pneumologica 2017 March;56(1):33-46

DOI: 10.23736/S0026-4954.16.01771-5

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Multidrug-resistant pathogens in respiratory diseases

Eva POLVERINO 1, Edmundo ROSALES-MAYOR 1, Antoni TORRES 2

1 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Institut d’Investigacions Biomèdiques August Pii Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain; 2 Department of Pulmonology, Institut Clínic Respiratori, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain


PDF


The threat of increasing multidrug-resistant infections (MDRI) is becoming a hot topic worldwide due to the potential risks in terms of global infections control and associated morbidity and mortality. Many potential reasons for this continuous increase of MDRI have been suggested and numerous projects are currently ongoing, which aim to investigate and stem this problem. In this review, MDRI has been analyzed in the context of the most relevant acute and chronic respiratory diseases, in order to provide an overall perspective of the topic and to identify future strategies of MDRI prevention or control in respiratory medicine. Mycobacterial infections were not considered, due to the large extent of this topic.


KEY WORDS: Multiple drug resistance - Respiratory tract infections - Pneumonia - Adult respiratory distress syndrome - Cystic fibrosis - Bronchiectasis

top of page